The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
Black Diamond Therapeutics Inc. (NASDAQ:BDTX) is one of the best biotech penny stocks to buy according to analysts. On ...
Researchers have found in a new study that an eGFRcys value that is 30% or more lower than eGFRcr was associated with ...
Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key ...
Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and ...
The National Institute for Health and Care Excellence (NICE) has recommended amivantamab (Rybrevant) plus lazertinib ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
Datopotamab deruxtecan-dlnk received FDA accelerated approval for EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy. Clinical trials showed a 45% overall response ...
For years, Nichole Jefferson battled a series of health problems as she juggled a stressful job in the tech industry while raising her daughter. Then, in 2003, she wasn’t feeling well and went to a ...
The epidermal growth factor receptor (EGFR)/ERBB family has evolved from a primordial, simple pathway of a single ligand receptor pair to a complex signalling network. Studies in invertebrates and in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback